348 related articles for article (PubMed ID: 15299085)
21. Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90.
Hardcastle A; Boxall K; Richards J; Tomlin P; Sharp S; Clarke P; Workman P; Aherne W
Assay Drug Dev Technol; 2005 Jun; 3(3):273-85. PubMed ID: 15971989
[TBL] [Abstract][Full Text] [Related]
22. The topoisomerase II-Hsp90 complex: a new chemotherapeutic target?
Barker CR; Hamlett J; Pennington SR; Burrows F; Lundgren K; Lough R; Watson AJ; Jenkins JR
Int J Cancer; 2006 Jun; 118(11):2685-93. PubMed ID: 16385570
[TBL] [Abstract][Full Text] [Related]
23. 17-AAG: mechanisms of antitumour activity.
Konstantinopoulos PA; Papavassiliou AG
Expert Opin Investig Drugs; 2005 Dec; 14(12):1471-4. PubMed ID: 16307487
[TBL] [Abstract][Full Text] [Related]
24. Regulation of glucocorticoid receptor steroid binding and trafficking by the hsp90/hsp70-based chaperone machinery: implications for clinical intervention.
Murphy PJ
Leukemia; 2005 May; 19(5):710-2. PubMed ID: 15759036
[No Abstract] [Full Text] [Related]
25. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.
Kelland LR; Sharp SY; Rogers PM; Myers TG; Workman P
J Natl Cancer Inst; 1999 Nov; 91(22):1940-9. PubMed ID: 10564678
[TBL] [Abstract][Full Text] [Related]
26. Heat shock protein inhibitor shows antitumor activity.
Dunn FB
J Natl Cancer Inst; 2002 Aug; 94(16):1194-5. PubMed ID: 12189221
[No Abstract] [Full Text] [Related]
27. Clinical development of 17-allylamino, 17-demethoxygeldanamycin.
Sausville EA; Tomaszewski JE; Ivy P
Curr Cancer Drug Targets; 2003 Oct; 3(5):377-83. PubMed ID: 14529389
[TBL] [Abstract][Full Text] [Related]
28. Challenges of PK/PD measurements in modern drug development.
Workman P
Eur J Cancer; 2002 Nov; 38(16):2189-93. PubMed ID: 12387843
[No Abstract] [Full Text] [Related]
29. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.
Chung YL; Troy H; Banerji U; Jackson LE; Walton MI; Stubbs M; Griffiths JR; Judson IR; Leach MO; Workman P; Ronen SM
J Natl Cancer Inst; 2003 Nov; 95(21):1624-33. PubMed ID: 14600095
[TBL] [Abstract][Full Text] [Related]
30. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
Yao Q; Nishiuchi R; Li Q; Kumar AR; Hudson WA; Kersey JH
Clin Cancer Res; 2003 Oct; 9(12):4483-93. PubMed ID: 14555522
[TBL] [Abstract][Full Text] [Related]
31. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
Schulte TW; Neckers LM
Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771
[TBL] [Abstract][Full Text] [Related]
32. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.
Neckers L
Curr Med Chem; 2003 May; 10(9):733-9. PubMed ID: 12678776
[TBL] [Abstract][Full Text] [Related]
33. Structure and in vivo function of Hsp90.
Pearl LH; Prodromou C
Curr Opin Struct Biol; 2000 Feb; 10(1):46-51. PubMed ID: 10679459
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells.
Villa R; Folini M; Porta CD; Valentini A; Pennati M; Daidone MG; Zaffaroni N
Carcinogenesis; 2003 May; 24(5):851-9. PubMed ID: 12771028
[TBL] [Abstract][Full Text] [Related]
35. HSP90 and the chaperoning of cancer.
Whitesell L; Lindquist SL
Nat Rev Cancer; 2005 Oct; 5(10):761-72. PubMed ID: 16175177
[TBL] [Abstract][Full Text] [Related]
36. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.
Workman P
Mol Cancer Ther; 2003 Feb; 2(2):131-8. PubMed ID: 12589030
[No Abstract] [Full Text] [Related]
37. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
[TBL] [Abstract][Full Text] [Related]
38. Identification of new biomarkers for clinical trials of Hsp90 inhibitors.
Zhang H; Chung D; Yang YC; Neely L; Tsurumoto S; Fan J; Zhang L; Biamonte M; Brekken J; Lundgren K; Burrows F
Mol Cancer Ther; 2006 May; 5(5):1256-64. PubMed ID: 16731758
[TBL] [Abstract][Full Text] [Related]
39. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
40. The stress response: implications for the clinical development of hsp90 inhibitors.
Whitesell L; Bagatell R; Falsey R
Curr Cancer Drug Targets; 2003 Oct; 3(5):349-58. PubMed ID: 14529386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
